Related Experiment Videos
The medical treatment of congestive heart failure
Insights
Adding vasodilators to standard treatments like diuretics can slow congestive heart failure progression and reduce mortality. Angiotensin-converting enzyme (ACE) inhibitors are currently preferred for their efficacy and tolerability.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Congestive heart failure (CHF) is a progressive syndrome associated with high mortality.
- Current treatments include diuretics and digitalis, but further interventions are needed.
Purpose of the Study:
- To evaluate the role of vasodilators in managing congestive heart failure.
- To determine the optimal timing and type of vasodilator therapy.
Main Methods:
- Review of existing data on vasodilator therapy in CHF patients.
- Analysis of studies involving diuretics, digitalis, and vasodilators, including ACE inhibitors.
- Consideration of early intervention in asymptomatic left ventricular dysfunction.
Main Results:
- Vasodilators, particularly ACE inhibitors, show promise in slowing CHF progression and reducing mortality.
- ACE inhibitors are better tolerated and more effective than conventional vasodilators.
- Early intervention with vasodilators may prevent deterioration in asymptomatic stages.
Conclusions:
- Vasodilator therapy should be considered as an addition to standard CHF treatment.
- ACE inhibitors are the preferred vasodilator class currently.
- Further research is needed to establish definitive recommendations for drug choice and patient selection, but early initiation may be beneficial.
Abstract:
The data herein presented provides persuasive evidence that in addition to diuretics, and probably digitalis (since all studies have included subjects taking this drug) patients with congestive heart failure should also be placed on a vasodilator regimen to slow the progression of the syndrome and to reduce its mortality. Firm recommendations for the choice of drug and the selection of patients likely to benefit from this treatment must await the results of further studies. At present, ACE inhibitors are preferred because they are usually better tolerated than conventional vasodilators and are clinically more effective. In regard to the question of when to begin vasodilator it is noteworthy that neurohormonal activation may occur early in the course of the disease, even before symptoms appear. If so, perhaps vasodilators should be initiated even in the asymptomatic stage of left ventricular dysfunction to prevent the progressive dilatation and deterioration that lead to clinical heart failure. The just published study of the efficacy of captopril in preventing the progression of left ventricular dilatation in patients with a recent anterior, transmural myocardial infarction supports this view. Further, ongoing studies, will help place these issues in their proper perspective.